ALFA Filings
Every announcement, straight from the exchange
Every financial results announcement on NSE and BSE that our alert engine sent, newest first.
Time
16,741 announcements with these filters
Austin Engineering Company approved audited FY26 financial results, reporting standalone net profit of ₹4.44 Crore. The board also noted the resignation of director Mr. Jagdishchandra B. Jagani.
Cool Caps Industries Ltd reported revenue from operations of ₹263.6 Cr (+85.2% YoY) and net profit of ₹3.2 Cr (-53.6% YoY) for H2 FY26.
Cool Caps Industries approved audited financial results for fiscal year 2026. The board also re-appointed M/s Ankit Khater & Associates as internal auditors.
One Point One Solutions Ltd reported revenue from operations of ₹96.2 Cr (+43.6% YoY) and net profit of ₹10.3 Cr (+18.4% YoY) for Q4 FY26.
One Point One Solutions reported annual consolidated revenue of ₹331.03 Crore. Net profit reached ₹38.21 Crore, reflecting strong fiscal performance for the year ended March 2026.
Indo Credit Capital Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and net profit of ₹0.1 Cr (+0.0% YoY) for Q4 FY26.
Indo Credit Capital approved audited standalone financial results for the year ended March 31, 2026. The company reported a total income of ₹0.28 Crore.
Futuristic Securities Ltd reported net profit of ₹0 Cr for Q4 FY26.
HPL Electric & Power Ltd reported revenue from operations of ₹519.7 Cr (+5.5% YoY) and net profit of ₹30.9 Cr (-17.2% YoY) for Q4 FY26.
Futuristic Securities approved its audited FY26 financial results, reporting annual total income of ₹11.26 Lakh. The board also re-appointed M/s. Roy Jacob & Co as secretarial auditors.
HPL Electric & Power reported audited FY26 results and recommended a Rs. 1.00 (10%) final dividend per share. Total annual consolidated income reached ₹1,815.33 Crore.
Varroc Engineering Ltd reported revenue from operations of ₹2,368 Cr (+12.8% YoY) and net profit of ₹70.5 Cr (+206.5% YoY) for Q4 FY26.
Varroc Engineering reported FY26 audited results and recommended a ₹1.50 per share dividend. The board also approved a ₹500 Crore fund raise via NCDs.
Alphageo (India) Ltd reported revenue from operations of ₹49.3 Cr (-30.2% YoY) and a net loss of ₹3 Cr for Q4 FY26.
Alphageo (India) Limited reported audited FY26 results and recommended a Rs. 5 per share dividend. The company also disclosed ongoing FEMA and tax-related contingent liabilities.
Oswal Yarns Ltd reported revenue from operations of ₹0.2 Cr (-66.7% YoY) and net profit of ₹0 Cr for Q4 FY26.
BYLD Capital Finance Ltd reported revenue from operations of ₹0.1 Cr and a net loss of ₹1.3 Cr for Q4 FY26.
Oswal Yarns approved audited financial results for the fiscal year ending March 31, 2026. The board meeting concluded with unmodified auditor reports for the period.
BYLD Capital Finance reported a ₹2.21 Crore annual loss alongside a ₹10.00 Crore rights issue completion. The company transitioned from Avasara Finance Limited during this period.
Ganesh Benzoplast Ltd reported revenue from operations of ₹111.5 Cr (+11.6% YoY) and net profit of ₹15.3 Cr for Q4 FY26.
Ganesh Benzoplast approved its FY26 audited standalone and consolidated financial results. The board also appointed new cost and internal auditors for the 2026-27 financial year.
Bombay Oxygen Investments Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and a net loss of ₹31.4 Cr for Q4 FY26.
Bombay Oxygen Investments approved FY2026 audited results and recommended a Rs.25 per share dividend. The company reported a net loss of ₹3.24 Crore for the year.
Iconik Sports and Events Ltd reported revenue from operations of ₹18.4 Cr (+44.9% YoY) and net profit of ₹1.1 Cr (-65.6% YoY) for Q4 FY26.
Iconik Sports And Events reported annual revenue of ₹45.82 Crore for FY2026. The board also approved shifting its registered office and re-appointing internal auditors.
Suraj Products reported its audited FY26 financial results and recommended a Rs.2.25 per share final dividend. Standalone annual revenue reached ₹303.79 Crore with a ₹18.85 Crore profit.
Medicamen Biotech Ltd reported revenue from operations of ₹60.6 Cr (+104.7% YoY) and net profit of ₹4.4 Cr (+131.6% YoY) for Q4 FY26.
Medicamen Biotech approved audited FY26 financial results and recommended a Rs. 1.00 per share final dividend. The board also appointed new cost and internal auditors.
KIOCL Ltd reported revenue from operations of ₹220.3 Cr (-10.6% YoY) and net profit of ₹53.4 Cr for Q4 FY26.
KIOCL Limited reported an annual total revenue of ₹708.26 Crore for fiscal year 2026. The company achieved a net profit of ₹16.57 Crore, signaling improved financial health.